Light

Keystone Lab Announces Addition of Delta-8 THC & CBD Metabolites Testing to its Testing Menu

Retrieved on: 
Monday, June 20, 2022

ASHEVILLE, N.C., June 20, 2022 /PRNewswire/ -- Keystone Lab , based in Asheville, NC, has officially added delta-8 THC & CBD metabolites testing to the testing menu on its clinical services line.

Key Points: 
  • ASHEVILLE, N.C., June 20, 2022 /PRNewswire/ -- Keystone Lab , based in Asheville, NC, has officially added delta-8 THC & CBD metabolites testing to the testing menu on its clinical services line.
  • Keystone Lab provides clinical and forensic toxicology testing services throughout the southeastern U.S. and is now one of only a few labs in the nation to offer delta-8 THC & CBD metabolites testing.
  • It is detected in low concentrations in most cannabis plants with percentages of delta-8 THC to delta-9 THC ranging from 0.1%-2%.
  • Beneficiaries of delta-8 THC & CBD metabolites testing include organizations that have a zero-tolerance policy for any type of substance such as addiction clinics and recovery centers.

Dermatologists Are the Leading Influencer for Cosmetic Procedures and Skin Care Decisions

Retrieved on: 
Monday, June 20, 2022

Rolling Meadows, IL, June 20, 2022 (GLOBE NEWSWIRE) -- Consumers turned to dermatologists to guide cosmetic procedures and skin care choices, as revealed in the 2021 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures .

Key Points: 
  • Rolling Meadows, IL, June 20, 2022 (GLOBE NEWSWIRE) -- Consumers turned to dermatologists to guide cosmetic procedures and skin care choices, as revealed in the 2021 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures .
  • Dermatologists rank as the number one influencer among 16 factors that impact consumers decisions to have a cosmetic procedure.
  • Cosmetic treatments are medical procedures, and board certified dermatologists are uniquely qualified to deliver safe, leading care with customized treatment plans for their patients, said ASDS President Sue Ellen Cox, MD.
  • Social media ranked as the second leading factor in buying decisions for skin care products and ranked third among factors influencing the decision to have a cosmetic treatment.

Vivid Sydney 2023 Dates and New Food Program Announced as the Lights Switch Off for 2022

Retrieved on: 
Sunday, June 19, 2022

Vivid Sydney 2023 will take place from Friday 26 May to Saturday 17 June and will feature for the first-time dedicated food programming - Vivid Food - which will sit alongside Light, Music and Ideas.

Key Points: 
  • Vivid Sydney 2023 will take place from Friday 26 May to Saturday 17 June and will feature for the first-time dedicated food programming - Vivid Food - which will sit alongside Light, Music and Ideas.
  • "Vivid Sydney provides a mid-year boon for restaurants, bars, cafes and retail in the central business district (CBD) and along the festival's footprint.
  • Vivid Sydney 2023 Expressions of Interest (EOI) for Light, Music, Ideas and Food will open on Saturday 18 June.
  • For all the latest information on Vivid Sydney 2023 sign up to receive MyVivid updates here .

Returning to New Zealand: SOFIA Travels to Christchurch for a Seventh and Final

Retrieved on: 
Sunday, June 19, 2022

About once a year, SOFIA temporarily moves its operating home to better observe celestial objects in the Southern Hemisphere.

Key Points: 
  • About once a year, SOFIA temporarily moves its operating home to better observe celestial objects in the Southern Hemisphere.
  • This year, SOFIA already deployed once to Santiago, Chile, for a quick, two-week deployment to observe the Large Magellanic Cloud.
  • Now, SOFIA is heading back to New Zealand for the seventh and final time.
  • "We are thrilled to be returning to Christchurch to continue to study and discover the infrared universe," said Naseem Rangwala, the SOFIA project scientist.

Annual Charity Golf Outing 'Jumping Jack to End Duchenne' Hosts "The Final Round"

Retrieved on: 
Saturday, June 18, 2022

WESTMINSTER, Colo., June 18, 2022 /PRNewswire/ -- For 19 years, the Knight family of Westminster, Colorado has supported the mission of Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), by hosting their annual Jumping Jack events each June. Angela and Darrell Knight, along with friends, family, and what seems like the entire community of Westminster, Colorado have fought to end Duchenne since their son Jack was a young boy. This year Jumping Jack will bring the community together again for "The Final Round" on Monday, June 20 to raise awareness for Duchenne, and to celebrate the life of Angela Knight.    

Key Points: 
  • Annual Golf Tournament that Supports Parent Project Muscular Dystrophy Will Celebrate Legacy of Beloved Mother Angela Knight.
  • She had a gift of crafting community and was a source of laughter, light, and love to everyone.
  • The Jumping Jack Golf Tournament is a unique opportunity to enjoy a top-notch golf experience on an absolutely beautiful course.
  • Register to join us for dinner and be a part of Jumping Jack Golf Tournament - The Final Round on June 20, 2022 at Legacy Ridge Golf Course.

SIGGRAPH 2022 Reveals Unique and Experiential Innovations in the Emerging Technologies and Immersive Pavilion Programs

Retrieved on: 
Friday, June 17, 2022

CHICAGO, June 17, 2022 /PRNewswire/ -- SIGGRAPH 2022 raises the stakes with 26 selected research projects out of more than 100 submissions from 27 countries as part of both its Emerging Technologies and Immersive Pavilion programs this summer. The chosen projects cover breakthroughs in the evolution of technology across many subfields of computer graphics and interactive techniques. The 49th annual conference will run 8–11 August in person, with on-demand talks from researchers available virtually 25 July–31 October 2022.

Key Points: 
  • "I'm thrilled to share the 2022 program, which showcases the latest innovations in computer graphics and interactive techniques across some really interesting use case scenarios," shared SIGGRAPH 2022 Emerging Technologies Chair Mk Haley.
  • The SIGGRAPH Emerging Technologies program continues to discover the next generation of contributors from around the world."
  • Highlights from Emerging Technologies program to be showcased in Vancouver include:
    Perceiving multiple tactile sensations in VR is one of the keys to enabling a compelling, immersive experience.
  • Access to SIGGRAPH 2022 Emerging Technologies and Immersive Pavilion programming is available at varying registration levels.

Insights on the Infant Phototherapy Device Global Market to 2030 - by Light Source, Configuration, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022

The "Infant Phototherapy Device Market: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Infant Phototherapy Device Market: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global infant phototherapy device market is expected to grow at a CAGR of 3.7% from 2021 to 2030.
  • The major factors that drive the growth of the global infant phototherapy device market include rise in prevalence of neonatal jaundice and advantages of phototherapy over other treatment methods.
  • The infant phototherapy device market is segmented on the basis of type of light lamp, configuration, end user, and region.

SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults

Retrieved on: 
Friday, June 17, 2022

NORTH CHICAGO, Ill., June 17, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD).4 In two induction and one maintenance clinical trials, SKYRIZI demonstrated significant improvements in endoscopic response (defined as a decrease of greater than 50% from the baseline Simple Endoscopic Score in CD [SES-CD] or for patients with isolated ileal disease and SES-CD of 4, at least a 2-point reduction from baseline) and clinical remission (defined as a Crohn's Disease Activity Index [CDAI] of less than 150), compared to placebo, as both an induction and maintenance therapy.4

Key Points: 
  • * "This approval provides healthcare professionals with a greatly needed additional option for treating the disruptive symptoms of Crohn's disease."
  • Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI.
  • SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of SKYRIZI globally.
  • Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

Engine Capital Sends Letter to the Board of Directors of SciPlay Regarding Ongoing IP Agreement Negotiations with Light & Wonder

Retrieved on: 
Friday, June 17, 2022

As you know, Light & Wonder, Inc. (Light & Wonder), SciPlays parent company, IPOed a portion of SciPlay in 2019 and continues to own 81% of SciPlay.

Key Points: 
  • As you know, Light & Wonder, Inc. (Light & Wonder), SciPlays parent company, IPOed a portion of SciPlay in 2019 and continues to own 81% of SciPlay.
  • In summary, we believe that an extension of this IP agreement is of little value to SciPlay and that potential conflicts of interest could lead SciPlay to provide an unnecessary payment to Light & Wonder.
  • According to the existing IP Agreement, SciPlay has non-exclusive access to Light & Wonders New Content for its existing games only.
  • It doesnt need to extend the IP agreement to have access to that content per the initial IP agreement.

Unilumin Light & Display Products Debut at InfoComm 2022

Retrieved on: 
Friday, June 17, 2022

LAS VEGAS, June 17, 2022 /PRNewswire/ --Unilumin participated in InfoComm 2022, an international professional audio-visual exhibition, and exhibited a series of innovative new LED display products and light & display solutions.

Key Points: 
  • LAS VEGAS, June 17, 2022 /PRNewswire/ --Unilumin participated in InfoComm 2022, an international professional audio-visual exhibition, and exhibited a series of innovative new LED display products and light & display solutions.
  • As a leader in the light and display industry, Unilumin adheres to scientific romanticism.
  • According to seven light & display scenarios, Unilumin has launched the integrated solutions of hardware + system + software + content + interactive light & display.
  • The exhibited light and display product matrix includes UpanelSII, URM III, USH and other professional products to be applied in mainstream fields such as xR virtual shooting, professional use, and commercial display.